BIIB074 Treatment A + BIIB074 Treatment B + BIIB074 Treatment C + BIIB074 Treatment D
Phase 1Completed 0 watching 0 views this week💤 Quiet
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Trigeminal Neuralgia (TN)
Conditions
Trigeminal Neuralgia (TN), Other Neuropathic Pain
Trial Timeline
Dec 1, 2016 → Feb 1, 2017
NCT ID
NCT02951221About BIIB074 Treatment A + BIIB074 Treatment B + BIIB074 Treatment C + BIIB074 Treatment D
BIIB074 Treatment A + BIIB074 Treatment B + BIIB074 Treatment C + BIIB074 Treatment D is a phase 1 stage product being developed by Biogen for Trigeminal Neuralgia (TN). The current trial status is completed. This product is registered under clinical trial identifier NCT02951221. Target conditions include Trigeminal Neuralgia (TN), Other Neuropathic Pain.
Hype Score Breakdown
Clinical
10
Activity
5
Company
7
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02951221 | Phase 1 | Completed |
Competing Products
7 competing products in Trigeminal Neuralgia (TN)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Galcanezumab | Eli Lilly | Approved | 85 |
| Erenumab-Aooe | Amgen | Phase 2 | 51 |
| Rimegepant + Placebo | Pfizer | Phase 2 | 51 |
| CNV1014802 + Placebo | Biogen | Phase 1 | 30 |
| CNV1014802 + Placebo | Biogen | Phase 2 | 49 |
| BIIB074 + Placebo | Biogen | Phase 3 | 74 |
| BIIB074 + Placebo | Biogen | Phase 3 | 74 |